RESEARCH · GHK-CU · DELIVERY
GHK-Cu and the Delivery Problem: Skin Permeation, Liposomes, Hydrogels and Copper Speciation
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. Our earlier article on GHK-Cu copper-peptide research covers its chemistry, fibroblast and wound-model findings and gene-expression work. This article asks a different question that the literature keeps returning to: how does a small, very water-soluble metallopeptide actually get where a study wants it, and how well do the papers show that it arrived intact? PurixLab’s GHK-Cu 50mg is supplied as a research material for laboratory research use only.
A hydrophilic complex with a stability profile of its own
A preformulation study of GHK-Cu measured octanol–buffer distribution coefficients (log D) between −2.38 and −2.49 across pH 4.5 to 7.4, confirming that it is highly hydrophilic. The peptide was susceptible to hydrolytic cleavage under basic and oxidative stress, and to a lesser extent under acidic stress, with histidine among three main degradation products. Surprisingly, it stayed stable in water and in pH 4.5–7.4 buffers for at least two weeks at 60 °C. It was compatible with Span 60 niosomes but less stable alongside the negatively charged lipid dicetyl phosphate [1].
A 2025 review adds that GHK-Cu and its palmitoylated relative Pal-GHK are widely used in cosmetic products, yet published information on their skin permeability, effectiveness and physicochemical properties is insufficient. Its authors note a surprising absence of clinical studies and say formulation may be challenging because the peptide is both highly water-soluble and unstable [2].
Skin-permeation studies are mostly in vitro
An early diffusion-cell study used a liposome membrane as a stratum corneum model. GHK-Cu permeated the membrane, and the peptide influenced the dynamics of copper-ion diffusion; the authors noted that transport of this complex through the stratum corneum had received very little attention [3]. A later ex vivo study applied copper as the tripeptide complex to isolated stratum corneum, heat-separated epidermis and dermatomed human skin in flow-through cells, and measured copper by ICP-MS over 48 hours. Copper reached the receptor fluid and was also retained in the tissue, which the authors read as a sign of potential transdermal delivery [4]. Note what was measured: copper, not intact GHK-Cu.
Microneedles are an active-delivery approach. Pre-treating human skin with a polymeric microneedle array let 134 nanomoles of peptide and 705 nanomoles of copper permeate in 9 hours, while almost no peptide or copper crossed intact skin; safety was assessed in cellular and porcine models, and no obvious skin irritation was observed [5].
A 2025 review of liposomal GHK-Cu concluded that transport of GHK-Cu-containing liposomes across skin has received little attention, calling this a research gap and an impetus for better methods [6].
Liposomes and carrier design
In one formulation study, anionic and cationic hydrogenated-lecithin liposomes of about 100 nm were made by thin-film hydration, freeze–thaw cycling and extrusion. For the selected carriers, encapsulation efficiency was 31.7% for the cationic and 20.0% for the anionic system. In vitro, GHK-Cu did not significantly change tyrosinase activity but gave 48.90% elastase inhibition [7]. Encapsulation efficiency is a formulation number, not a biological outcome: roughly two-thirds to four-fifths of the peptide was not entrapped.
In mice, liposomal GHK-Cu increased proliferation of human umbilical vein endothelial cells by 33.1% and raised VEGF and FGF-2 expression. In a scald model, angiogenesis was better than with free GHK-Cu and wound healing time was shortened to 14 days [8]. That is an animal result in one wound model, not evidence of human effect.
Hydrogels and scaffolds
Materials-science groups now load or graft GHK-Cu into wound-dressing matrices. A self-assembling RADA16 nanofiber functionalised with GHK to chelate copper accelerated wound closure, collagen deposition and tissue remodelling in healthy and diabetic mice, with upregulated eNOS and CD31 [9]. A food-derived hydrogel of oxidised konjac glucomannan and egg white loaded with GHK-Cu showed antibacterial and anti-inflammatory properties and promoted neovascularisation in infected wounds [10]. In both studies the carrier is itself bioactive or structural, which complicates attributing effects to the peptide alone.
The human evidence is small
A randomised study of topical GHK-Cu skin care after CO2 laser resurfacing had 13 patients complete the protocol. Blinded and computer-assisted evaluations found no significant difference between groups in erythema resolution, wrinkles or overall skin quality; only a patient questionnaire favoured GHK-Cu for overall skin quality [11]. A 2026 evidence-mapping review states that clinical evidence for GHK-Cu remains sparse and does not meet contemporary active-entity quality standards, that historical cosmetic reports are small or incompletely characterised, and that an ongoing phase 2 acute-wound registration (NCT07437586) has no efficacy results and cannot be used as evidence of clinical translation [12].
What remains unknown
- Speciation. The same review found that delivery studies often report particle size, polydispersity, encapsulation efficiency and bulk release, but usually do not resolve molar copper occupancy, labile copper, or release of intact GHK-Cu versus apo-GHK or free copper [12].
- Comparability. Its authors did not pool results because the active entities, formulations, models and endpoints were not quantitatively commensurable, and they conclude that GHK-Cu is a promising but unproven therapeutic cargo rather than a clinically validated drug [12].
- Intact delivery in skin. Permeation papers that quantify copper alone cannot show how much peptide arrived intact [4,5].
- Human data. Controlled studies using well-characterised material are almost absent [2,11].
GHK-Cu 50mg at PurixLab
GHK-Cu 50mg: a labelled lyophilized research vial with 50mg per vial, C$49 per vial (CAD, before tax), supplied for laboratory research only. It is not a cosmetic; our separate Copper Facial Mask is the finished cosmetic product. Batch documentation is available on request. Product page: purixlab.com/product/ghk-cu-50mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Badenhorst T, Svirskis D, Wu Z. Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery. Pharm Dev Technol. 2016;21(2):152-60. PubMed 25384620 · doi:10.3109/10837450.2014.979944
- Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts. 2025;15:30071. PubMed 39963574 · PMC11830136 · doi:10.34172/bi.30071
- Mazurowska L, Mojski M. Biological activities of selected peptides: skin penetration ability of copper complexes with peptides. J Cosmet Sci. 2008;59(1):59-69. PubMed 18350235
- Hostynek JJ, Dreher F, Maibach HI. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflamm Res. 2010;59(11):983-8. PubMed 20703511 · PMC2945467 · doi:10.1007/s00011-010-0214-4
- Li H, Low YS, Chong HP, et al. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res. 2015;32(8):2678-89. PubMed 25690343 · doi:10.1007/s11095-015-1652-z
- Ogórek K, Nowak K, Wadych E, et al. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Molecules. 2025;30(1):136. PubMed 39795193 · PMC11721469 · doi:10.3390/molecules30010136
- Dymek M, Olechowska K, Hąc-Wydro K, et al. Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application. Pharmaceutics. 2023;15(10):2485. PubMed 37896245 · PMC10610410 · doi:10.3390/pharmaceutics15102485
- Wang X, Liu B, Xu Q, et al. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen. 2017;25(2):270-278. PubMed 28370978 · doi:10.1111/wrr.12520
- Yang X, Zhang Y, Huang C, et al. Biomimetic Hydrogel Scaffolds with Copper Peptide-Functionalized RADA16 Nanofiber Improve Wound Healing in Diabetes. Macromol Biosci. 2022;22(8):e2200019. PubMed 35598070 · doi:10.1002/mabi.202200019
- Chen H, Yang P, Xue P, et al. Food-Derived Tripeptide-Copper Self-Healing Hydrogel for Infected Wound Healing. Biomater Res. 2025;29:0139. PubMed 39902373 · PMC11788471 · doi:10.34133/bmr.0139
- Miller TR, Wagner JD, Baack BR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. PubMed 16847171 · doi:10.1001/archfaci.8.4.252
- Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics. 2026;18(9):1077. PubMed 42797253 · PMC13610439 · doi:10.3390/pharmaceutics18091077